Bripressia Plus 2 mg/ml + 5 mg/ml, eye drops

Reduction of intraocular pressure (IOP) in adults patients with chronic open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers.

Bripressia Plus consists of two active substances: brimonidine tartrate and timolol maleate. These two components decrease elevated intraocular pressure (IOP) by complementary mechanisms of action and the combined effect results in additional IOP reduction compared to either compound administered alone. Bripressia Plus has a rapid onset of action.

Brimonidine tartrate is an alpha-2 adrenergic receptor agonist that is 1,000-fold more selective for the alpha-2 adrenoceptor than the alpha-1 adrenoreceptor. This selectivity results in no mydriasis and the absence of vasoconstriction in microvessels associated with human retinal xenografts.

It is thought that brimonidine tartrate lowers IOP by enhancing uveoscleral outflow and reducing aqueous humour formation.

Timolol is a beta-1 and beta-2 non-selective adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anaesthetic (membrane-stabilising) activity. Timolol lowers IOP by reducing aqueous humour formation. The precise mechanism of action is not clearly established, but inhibition of the increased cyclic AMP synthesis caused by endogenous beta-adrenergic stimulation is probable.